COMPARE · Data as of August 21, 2026
CNC vs OSCR
Verdict: Side-by-side breakdown using the Bull Rankings model. CNC scored 57.6, OSCR scored 70.4 — OSCR leads.
Compare another set
CNC
Centene Corporation
57.6
$65.02 · $32.1B
fundamentals as of
Score gap
12.8
OSCR leads
OSCR
Oscar Health, Inc.
70.4
$32.04 · $9.9B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- Fastest growthOSCR+27.5%
- Strongest balance sheetOSCR0.23
- Highest qualityOSCR79 / 100
- Largest discount to fair valueCNC-77%
Side by side · every name on one set of axes
The model, pillar by pillar (0–100 each)
CNC
stronger →← stronger
OSCR
27
Qualityreturns · margins · balance sheet
79
86
Growthrevenue & earnings expansion
95
82
Valuevaluation vs sector peers
46
OSCR is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
CNC
OSCR
$9.0bB+
FCF
$4.4bB
+19.4%B+
Rev
+27.5%A-
0.71C+
D/E
0.23B
0.2xA
P/S
—
0.88B+
PEG
3.24D
—
P/E
24.6xB
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
CNC
OSCR
77% below
Price vs fair valuelower is cheaper
76% below
decline
Growth the price implies10-yr FCF · lower = less priced in
decline
+300%
1-yr DCF upside
+297%
+330%
5-yr DCF upside
+319%
+377%
10-yr DCF upside
+349%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
The companies
CNCCentene Corporation
Why now
Healthcare Plans · market cap $32.1b. 6% off the 52-week high of $69.36. Revenue growing +19%, comfortably above the S&P median. PEG 0.88 — paying under fair value for the growth rate. 18 sell-side analysts rate this a Buy with a mean 1-yr target of $71.67 (implying +10% upside).
Moat
Turnaround / out-of-favor name — GAAP-unprofitable for now, so the durability case is forward-looking: it rests on a recovery (margin normalization, a cyclical upturn or restructuring) or an un-monetized asset (IP / network effects / first-mover position) rather than on current reported results.
Risk
Currently unprofitable (margin -2.8%) — path to GAAP profitability is the core thesis risk. ROE -20% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
OSCROscar Health, Inc.
Why now
Healthcare Plans · market cap $9.9b. 4% off the 52-week high of $33.48. Revenue growing +27% — in hypergrowth territory. 10 sell-side analysts rate this a Hold with a mean 1-yr target of $30.40 (implying -5% upside).
Moat
ROE 34% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong.
Risk
Beta 2.38 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Net margin 3.6% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where CNC and OSCR diverge
On the headline score the gap is 12.8 points in favor of OSCR. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- QualityCNC 27.1 · OSCR 79.2OSCR +52.1
- ValueCNC 81.9 · OSCR 46.2CNC +35.7
- GrowthCNC 86.0 · OSCR 95.3OSCR +9.3
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.